Published in Blood Weekly, August 23rd, 2001
The study will continue for four more weeks, at which time final results will be analyzed and announced.
"PHER-O2's predecessor, Fluosol, which is the only oxygen-carrying synthetic red blood cell substitute to have received U.S. Food and Drug Administration (FDA) approval, required freezing to ensure stability," Thomas C. Drees, PhD, Sanguine Corporation, stated. "PHER-O2's emulsification formulation, currently being tested for stability, does not require...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.